Novo Nordisk A/S (0QIU)
LSE
Closed
Aug 24, 2026
Day's Range
297.9552 wk Range
225.00Overview - 0QIU - Novo Nordisk A/S
Key Statistics
Valuation
Enterprise Value
3.03T
P/E (Trailing)
‪19.94‬
PEG Ratio
‪-0.97‬
Price / Sales (TTM)
‪6.18‬
Price / Book
‪14.68‬
EV / EBITDA
‪32.64‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪33.39%‬
Operating Margin
‪43.20%‬
Return on Assets
‪21.75%‬
Return on Equity
‪81.53%‬
Ownership
Shares Outstanding
4.42B
Float
3.21B
Price stats
Beta
‪0.21‬
50-Day Avg
‪311.09‬
200-Day Avg
‪298.82‬
Dividends
Payout Ratio
‪41.65%‬
Frequency
Semi-Annual
Market Cap - 0QIU - Novo Nordisk A/S
Peers - 0QIU - Novo Nordisk A/S
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on LSE.
- 0QIULSENovo Nordisk A/S1.24TMarket Cap-23.24%52-week change20.09P/E (Trailing)‪33.39%‬Profit Margin
- AZNLSEAstraZeneca PLC22.41TMarket Cap+29.32%52-week change28.74P/E (Trailing)‪17.18%‬Profit Margin
- GSKLSEGSK plc7.68TMarket Cap+23.40%52-week change16.26P/E (Trailing)‪14.52%‬Profit Margin
- 0Q1GLSEEli Lilly and Company686.33BMarket Cap+54.90%52-week change1.56P/E (Trailing)‪33.52%‬Profit Margin
- 0QCVLSEAbbVie Inc.478.52BMarket Cap+21.83%52-week change54.73P/E (Trailing)‪15.50%‬Profit Margin
- 0QAHLSEMerck & Co., Inc.383.85BMarket Cap+44.02%52-week change63.23P/E (Trailing)‪5.33%‬Profit Margin
- 0K9ELSENovartis AG Sponsored ADR367.33BMarket Cap+20.90%52-week change0.15P/E (Trailing)‪22.50%‬Profit Margin
Profile Summary - 0QIU - Novo Nordisk A/S
About
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
